Icrucumab
Icrucumab (IMC-18F1) is a human monoclonal antibody designed for the treatment of solid tumors.[1][2]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | VEGFR-1 |
| Clinical data | |
| Other names | IMC-18F1 |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6514H10024N1756O2032S42 |
| Molar mass | 146796.63 g·mol−1 |
 N Y (what is this?) (verify) | |
Icrucumab was developed by ImClone Systems Inc. It is undergoing Phase I trials.[3]
References
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Icrucumab" (PDF). American Medical Association.
- LoRusso PM, Krishnamurthi S, Youssoufian H, Hall N, Fox F, Dontabhaktuni A, Grebennik D, Remick S (April 2014). "Icrucumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor-1, in the treatment of patients with advanced solid malignancies: a Phase 1 study". Invest New Drugs. 32 (2): 303–11. doi:10.1007/s10637-013-9998-8. PMID 23903897. S2CID 34756277.
- Clinical trial number NCT00782002 for "Safety Study of IMC-18F1, to Treat Advanced Solid Tumors in Subjects That no Longer Respond to Standard Therapy" at ClinicalTrials.gov
Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Bone |
| ||||||||
| Musculoskeletal |
| ||||||||
| Circulatory |
| ||||||||
| Neurologic |
| ||||||||
| Angiogenesis inhibitor |
| ||||||||
| Growth factor |
| ||||||||
| |||||||||
Growth factor receptor modulators | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Angiopoietin |
| ||||||||||
| CNTF |
| ||||||||||
| EGF (ErbB) |
| ||||||||||
| FGF |
| ||||||||||
| HGF (c-Met) |
| ||||||||||
| IGF |
| ||||||||||
| LNGF (p75NTR) |
| ||||||||||
| PDGF |
| ||||||||||
| RET (GFL) |
| ||||||||||
| SCF (c-Kit) | |||||||||||
| TGFβ |
| ||||||||||
| Trk |
| ||||||||||
| VEGF |
| ||||||||||
| Others |
| ||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.